{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:03:09Z","timestamp":1784296989862,"version":"3.55.0"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100015516","name":"Revance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015516","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>DaxibotulinumtoxinA for injection (DAXI), a novel botulinum toxin (BoNT) formulated with a custom\u2010engineered peptide, was recently approved for treating cervical dystonia (CD). DAXI demonstrated a long duration of symptom relief in Phase 3 trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To report findings from PrevU, an early experience, real\u2010world observational program initiated following DAXI's FDA approval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Movement disorder specialists were provided with DAXI to treat CD patients per routine clinical practice, and were surveyed on dosing patterns and treatment intervals across the first three\u2009cycles of DAXI as doses were optimized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 234 CD patients (206 receiving BoNT treatment and 28 BoNT\u2010na\u00efve) received a total of 589 DAXI treatments. Among patients with prior BoNT therapy, breakthrough symptoms within 12\u2009weeks of prior BoNT therapy was the most common reason for patient selection (76.2%), and onabotulinumtoxinA was the most common prior toxin (68.4%). DAXI dose was titrated from a mean of 244.4\u2009U (median 250\u2009U) to 314.7\u2009U (median 300\u2009U) by Cycle 3. The ratio of DAXI dose to normalized prior BoNT dose was approximately 1.1:1 at initiation and 1.4:1\u00a0at Cycle 3. The mean (SD) time to re\u2010treatment across all DAXI cycles was 16.1 (5.6) weeks for all patients and 15.7 (4.5) weeks for patients with a history of breakthrough before 12\u2009weeks with prior toxin. The most common adverse events were muscle weakness (2.4% of treatments), injection pain (1.4% of treatments), and dysphagia (0.3% of treatments).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real\u2010world setting, DAXI demonstrated extended clinical benefit and a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mdc3.70477","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T06:53:57Z","timestamp":1770188037000},"page":"1644-1652","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>DaxibotulinumtoxinA<\/scp>\n                    for Injection in Adults with Cervical Dystonia: Clinical Insights from a Real\u2010World Early Experience Program"],"prefix":"10.1002","volume":"13","author":[{"given":"Laxman","family":"Bahroo","sequence":"first","affiliation":[{"name":"MedStar Georgetown University Hospital  Washington Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Ellenbogen","sequence":"additional","affiliation":[{"name":"Quest Research Institute  Farmington Hills Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6369-1203","authenticated-orcid":false,"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[{"name":"University of South Florida  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6508-2640","authenticated-orcid":false,"given":"Han S.","family":"Lee","sequence":"additional","affiliation":[{"name":"The Permanente Medical Group  San Leandro California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McAllister","sequence":"additional","affiliation":[{"name":"New England Institute for Neurology and Headache  Stamford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul T.","family":"Patel","sequence":"additional","affiliation":[{"name":"Kansas City Bone &amp; Joint Clinic  Overland Park Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid","family":"Kazerooni","sequence":"additional","affiliation":[{"name":"Revance  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Gross","sequence":"additional","affiliation":[{"name":"Revance  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sparrow","sequence":"additional","affiliation":[{"name":"Revance  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor J.","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Revance  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Hollander","sequence":"additional","affiliation":[{"name":"Revance  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00035"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-013-1048-3"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0023-6"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7586-2"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325193"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100052240"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10378-5"},{"key":"e_1_2_9_9_1","unstructured":"Allergan.BOTOX\u00ae (onabotulinumtoxinA) for injection for intramuscular intradetrusor or intradermal use prescribing information;2023.https:\/\/www.rxabbvie.com\/pdf\/botox_pi.pdf. Accessed June 24 2024."},{"key":"e_1_2_9_10_1","unstructured":"Ispsen Biopharm.DYSPORT (abobotulinumtoxinA) for injection for intramuscular use prescribing information;2016.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125274s107lbl.pdf. Accessed June 24 2024."},{"key":"e_1_2_9_11_1","unstructured":"Merz.XEOMIN (IncobotulinumtoxinA) for injection for intramuscular or intraglandular use prescribing information;https:\/\/www.xeominaesthetic.com\/wp-content\/uploads\/2019\/05\/XEOMIN-Full-Prescribing-Information-including-MedGuide.pdf. Accessed March 26 2024."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.653726"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10217-7"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S106560"},{"key":"e_1_2_9_15_1","unstructured":"Revance.DAXXIFY\u00ae (daxibotulinumtoxinA\u2010Lanm) for injection for intramuscular use;https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761127s002lbl.pdf. Accessed March 26 2024."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2024.107364"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2023.2251399"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2011.05.012"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2018.11.273"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203363"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70104"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins17030133"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000208091"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2024.107383"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-020-02027-z"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050345"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10252"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins16080362"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins16100442"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10120535"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mdc3.70477","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:13:07Z","timestamp":1784293987000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.70477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/mdc3.70477"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.70477","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"2025-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}